Literature DB >> 24357096

Genetic susceptibility to lung cancer based on candidate genes in a sample from the Mexican Mestizo population: a case-control study.

R Pérez-Morales1, I Méndez-Ramírez, H Moreno-Macias, A D Mendoza-Posadas, O C Martínez-Ramírez, C Castro-Hernández, M E Gonsebatt, J Rubio.   

Abstract

BACKGROUND: Lung cancer (LC) is the leading cause of mortality caused by neoplasias worldwide. Although cigarette smoking is the primary cause, not all smokers develop LC. Polymorphic variations in genes associated with carcinogen metabolism, DNA repair, and cell-cycle dysregulation may alter an individual risk of developing LC. A polygenic cancer model was proposed, which considers genetic susceptibility to cancer is a global mechanism and suggests that it might be defined by the contributions of low-risk alleles in several candidate genes. This study focused on the analysis of 15 polymorphisms in 12 low-penetrance genes in a case-control study of a sample of Mexican Mestizo population.
METHODS: A case-control study was performed with a total of 572 unrelated individuals, including 190 cases with a primary LC diagnosis and 382 healthy controls. The polymorphic status of the individuals was determined by TaqMan probe and RFLP techniques. The association between LC and genotype score (GS) was assessed by logistic regression.
RESULTS: The results suggests a protective effect of the genotypes Arg/Lys of AhR rs2066853 (odds ratio [OR] 0.55, p = 0.03), Ile/Val of CYP1A1 rs1048943 (OR 0.49, p = 0.009), Tyr/His of EPHX1 rs1051740 (OR 0.53, p = 0.03), and A/A of CCND1 rs603965 (OR 0.44, p = 0.02). Analyses using the GS suggest that average cases have a larger number of risk alleles than controls (Student's t test -4.85, p = 0.001; OR 1.25, p < 0.001).
CONCLUSIONS: Our results suggest significant differences between the GS for the cases and controls, which support the hypothesis underlying the additive and polygenic models for lung cancer risk depending on the polymorphisms in low-penetrance genes.

Entities:  

Mesh:

Year:  2013        PMID: 24357096     DOI: 10.1007/s00408-013-9536-7

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  32 in total

1.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.

Authors:  Sholom Wacholder; Stephen Chanock; Montserrat Garcia-Closas; Laure El Ghormli; Nathaniel Rothman
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

2.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

3.  Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.

Authors:  H Dean Hosgood; Idan Menashe; Min Shen; Meredith Yeager; Jeff Yuenger; Preetha Rajaraman; Xingzhou He; Nilanjan Chatterjee; Neil E Caporaso; Yong Zhu; Stephen J Chanock; Tongzhang Zheng; Qing Lan
Journal:  Carcinogenesis       Date:  2008-08-01       Impact factor: 4.944

Review 4.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.

Authors:  Linda M Dong; John D Potter; Emily White; Cornelia M Ulrich; Lon R Cardon; Ulrike Peters
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

5.  Effects of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population.

Authors:  R C Sobti; Pushpinder Kaur; Satinder Kaur; Jagmohan Singh; A K Janmeja; S K Jindal; J Kishan; Sara Raimondi
Journal:  Cancer Genet Cytogenet       Date:  2006-10-15

6.  The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies.

Authors:  Zhiwei Chen; Ziming Li; Xiaomin Niu; Xiangyun Ye; Yongfeng Yu; Shun Lu; Zhen Chen
Journal:  Mutagenesis       Date:  2011-03-14       Impact factor: 3.000

Review 7.  Architecture of inherited susceptibility to common cancer.

Authors:  Olivia Fletcher; Richard S Houlston
Journal:  Nat Rev Cancer       Date:  2010-05       Impact factor: 60.716

Review 8.  Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis.

Authors:  C Carlsten; G S Sagoo; A J Frodsham; W Burke; J P T Higgins
Journal:  Am J Epidemiol       Date:  2008-02-12       Impact factor: 4.897

9.  Predicting the future for people with lung cancer.

Authors:  Yang Xie; John D Minna
Journal:  Nat Med       Date:  2008-08       Impact factor: 53.440

10.  A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Authors:  Shanbeh Zienolddiny; Daniele Campa; Helge Lind; David Ryberg; Vidar Skaug; Lodve B Stangeland; Federico Canzian; Aage Haugen
Journal:  Carcinogenesis       Date:  2008-02-06       Impact factor: 4.944

View more
  4 in total

1.  Association between EPHX1 rs1051740 and lung cancer susceptibility: a meta-analysis.

Authors:  Peng Zhang; Youzhi Zhang; Haihua Yang; Wenjing Li; Xiaodong Chen; Feng Long
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease.

Authors:  Radka Václavíková; David J Hughes; Pavel Souček
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

Review 3.  CYP1A1 and GSTP1 gene variations in breast cancer: a systematic review and case-control study.

Authors:  Sumaira Akhtar; Ishrat Mahjabeen; Zertashia Akram; Mahmood Akhtar Kayani
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

4.  Lack of association between multiple polymorphisms in aryl hydrocarbon receptor (AhR) gene and cancer susceptibility.

Authors:  He Li; Li Luo; Dan Wang; Jun Duan; Rui Zhang
Journal:  Environ Health Prev Med       Date:  2020-12-05       Impact factor: 3.674

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.